Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 2
1973 1
1975 3
1977 4
1979 1
1981 1
1982 1
1983 3
1985 2
1986 2
1987 6
1988 2
1989 1
1990 3
1991 3
1992 3
1993 5
1994 6
1995 8
1996 3
1997 4
1998 5
1999 7
2000 12
2001 16
2002 59
2003 72
2004 40
2005 51
2006 70
2007 82
2008 100
2009 127
2010 156
2011 157
2012 169
2013 184
2014 196
2015 186
2016 209
2017 204
2018 218
2019 221
2020 284
2021 282
2022 232
2023 197
2024 209
2025 217
2026 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,570 results

Results by year

Filters applied: . Clear all
Page 1
Atomically accurate de novo design of antibodies with RFdiffusion.
Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, Biswas R, Yu Y, Shrock EL, Ault R, Leung PJY, Huang B, Goreshnik I, Tam J, Carr KD, Singer B, Criswell C, Wicky BIM, Vafeados D, Sanchez MG, Kim HM, Torres SV, Chan S, Sun SM, Spear T, Sun Y, O'Reilly K, Maris JM, Sgourakis NG, Melnyk RA, Liu CC, Baker D. Bennett NR, et al. bioRxiv [Preprint]. 2025 Feb 28:2024.03.14.585103. doi: 10.1101/2024.03.14.585103. bioRxiv. 2025. Update in: Nature. 2026 Jan;649(8095):183-193. doi: 10.1038/s41586-025-09721-5. PMID: 38562682 Free PMC article. Updated. Preprint.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. Kim HJ, et al. Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18. Neurology. 2015. PMID: 25695963 Free PMC article. Review.
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes MP, Weinshenker B, Yamout B, Fujihara K. Correale J, et al. Lancet Neurol. 2024 Oct;23(10):1035-1049. doi: 10.1016/S1474-4422(24)00256-4. Lancet Neurol. 2024. PMID: 39304243 Review.
Forever young.
Sastre-Garriga J, Graves J, Ontaneda D, Rocca MA, Chard DT, Toosy A, van der Walt A, Hedström AK, Moccia M, Brownlee W, Kim HJ, Thompson AJ. Sastre-Garriga J, et al. Mult Scler. 2025 Jan;31(1):3-5. doi: 10.1177/13524585241311154. Mult Scler. 2025. PMID: 39784932 No abstract available.
Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Kwon YN, Kim B, Kim JS, Park KS, Seo DY, Kim H, Lee EJ, Lim YM, Ju H, Chung YH, Min JH, Nam TS, Kim S, Sohn E, Shin KJ, Seok JM, Kim S, Bae JS, Lee S, Oh SI, Jung YJ, Park J, Kim SH, Kim KH, Kim HJ, Jung JH, Kim SJ, Kim SW, Jang MJ, Sung JJ, Waters P, Shin HY, Kim SM. Kwon YN, et al. JAMA Neurol. 2024 Oct 1;81(10):1073-1084. doi: 10.1001/jamaneurol.2024.2811. JAMA Neurol. 2024. PMID: 39226035 Free PMC article.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
3,570 results